Actualités

BWXT expands its commercial nuclear portfolio through nuclear medicine, isotope production and radiopharmaceutical capabilities.

BWX's second quarter performance reflected robust demand across both its government and commercial nuclear businesses, with revenue growth led by increased activity in commercial nuclear power and aftermarket services. Management pointed to strong operational execution and productivity improvements, particularly in Government Operations, as key contributors. CEO Rex Geveden highlighted the company's “position of strength with exposure across the nuclear value chain,” and noted that the recent sa

Babcock (NYSE:BW) reported higher second-quarter revenue, net income and adjusted EBITDA, citing increased project activity and demand for reliable power generation from utility, industrial and data center customers. Chairman and Chief Executive Officer Kenny Young said the company raised its full-

Commercial nuclear revenue surged 72% as management raised full-year guidance.

One turnaround story bleeds cash while the other generates it steadily. The valuation gap between them tells an important story about risk and reward.

Congresswoman April McClain Delaney recently disclosed up to $1.4 million worth of new stock trades. Wall Street is paying attention because she sits on the House Science, Space, and Technology Committee. BWX Technologies, Inc. (NYSE:BWXT) and Entegris, Inc. (NASDAQ:ENTG) are among the top buys in the politician’s portfolio that are getting limelight. Let’s look at […]

Hyperscalers are signing decade-long power deals that would have seemed absurd three years ago, and three nuclear stocks sit at the center of that shift as an operator, a fuel producer, and a components maker each tell a very different story about risk and reward.

BWX Technologies, Inc. reported past Q2 2026 results with sales of US$901.63 million and net income of US$89.01 million, raised full‑year 2026 revenue guidance to about US$3.80 billion, and its board declared a US$0.27 per‑share quarterly dividend payable on September 4, 2026. At the same time, BWX Technologies agreed to sell most of its medical business for up to US$800 million, sharpening its focus on core nuclear markets and advanced reactor technologies. We’ll now examine how the raised...

BWXT raises its 2026 outlook as stronger operations support higher guidance, while a medical divestiture and PCG deal sharpen its nuclear focus.

BWX Technologies (NYSE:BWXT) has agreed to sell its medical business to Nordic Capital, while keeping a minority interest and technical involvement. The company has also signed a fuel fabrication agreement with Clean Core Thorium Energy related to future nuclear fuel deployments. These moves indicate a shift in BWX Technologies’ business mix toward core nuclear operations and advanced fuel capabilities. BWX Technologies enters these transactions with a share price of $173.79 and a 5 year...

Moby summary of BWX Technologies, Inc.'s Q2 2026 earnings call

BWXT posts 18% revenue growth, raises full-year guidance, and sharpens focus on nuclear core markets with $800 million medical business sale.

BWX Technologies (NYSE:BWXT) reported second-quarter 2026 revenue growth of 18% and raised its full-year financial outlook, citing continued demand across nuclear national security and commercial power markets. Second-quarter revenue reached $902 million, including 9% organic growth, while adjusted

BWX (BWXT) delivered earnings and revenue surprises of +5.94% and +1.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aerospace and defense company BWX (NYSE:BWXT) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 18% year on year to $901.6 million. Its non-GAAP profit of $1.07 per share was 2.7% above analysts’ consensus estimates.

Aerospace and defense company BWX (NYSE:BWXT) will be reporting earnings this Monday afternoon. Here’s what to expect.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.

Westinghouse Electric says it plans to start construction on 10 new reactors in the U.S. by 2030. Its IPO could be a blockbuster.

BWXT heads into Q2 with nuclear, medical and defense demand supporting sales, while earnings are expected to edge lower.

Vertiv's latest quarter hit $3.3 billion as data center demand surges, while BWX Technologies maintains steady defense contracts.

JPMorgan just pointed investors toward a fast-rising player in AI nuclear energy. On July 27, 2026, the bank started coverage of BWX Technologies (BWXT) with an overweightrating and a $230 price target. That target runs through December 2027 and sits about 30% above where the stock traded when the ...

BWX Technologies (BWXT) stock has recently drawn attention after a period of weaker performance, with the share price down 7% over the past week and 17% over the past month. See our latest analysis for BWX Technologies. The recent slide in BWX Technologies’ share price, including a 27.24% decline over the past 90 days, contrasts with its 3-year total shareholder return of 134.56% and 5-year total shareholder return of 215.24%. This points to fading short term momentum against a stronger long...

BWX Technologies has delivered very strong share price gains over the past five years, yet its current valuation checks now suggest the stock may be pricing in a premium to its intrinsic value. The Discounted Cash Flow (DCF) intrinsic value estimate and the earnings based multiples both point to BWX Technologies trading on the expensive side after this long run. The stock has returned 215.2% over the past five years, which puts extra focus on whether the current price still leaves room for a...

US-Saudi nuclear deal could reshape the energy landscape. See how nuclear ETFs may offer diversified exposure to companies positioned to benefit.

One company has logged eight straight quarters of $600M+ revenue; the other just crossed $1.6M in its first full quarter of sales.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

XE and BWXT offer two distinct paths into the growing nuclear sector, from advanced reactor development to established government-backed nuclear operations.

SMR's regulatory lead and $1 billion liquidity set the stage, but contracts, financing and dilution will decide its commercial success.

NuScale's valuation has reset, but its buy case still hinges on turning approved technology and project pipelines into contracts, financing and revenues.

Polen Capital, an investment management company, released its second-quarter 2026 investor letter for “Polen 5Perspectives Small-Mid Growth Strategy”. A copy of the letter can be downloaded here. Polen 5Perspectives Small-Mid Growth Composite Portfolio returned 28.4% gross and 28.2% net of fees, respectively, compared to the 24.0% return of the Russell 2500 Growth Index. Markets rebounded strongly […]